[{"orgOrder":0,"company":"MSN Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cangrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"MSN Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"MSN Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MSN Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Cangrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"GLAND PHARMA LIMITED","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GLAND PHARMA LIMITED \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"GLAND PHARMA LIMITED \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Caen","sponsor":"Terumo","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cangrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University Hospital, Caen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Caen \/ Terumo","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital, Caen \/ Terumo"},{"orgOrder":0,"company":"CHIESI USA INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cangrelor","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"CHIESI USA INC","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CHIESI USA INC \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CHIESI USA INC \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Cangrelor

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : Kengreal-Generic (cangrelor) is a P2Y12 platelet inhibitor, which is indicated for the treatment of periprocedural myocardial infarction.

                          Product Name : Kengreal-Generic

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 12, 2025

                          Lead Product(s) : Cangrelor

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : KENGREAL (cangrelor) for Injection is a P2Y12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce risk of MI, repeat coronary revascularization, and stent thrombosis (ST) in patients.

                          Product Name : Kengreal

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 01, 2022

                          Lead Product(s) : Cangrelor

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : Company rolled out the first generic version of Cangrelor is an intravenous platelet P2Y12 antagonist ) used to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 01, 2021

                          Lead Product(s) : Cangrelor

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          University Hospital, Caen

                          Country arrow
                          OPRD
                          Not Confirmed

                          University Hospital, Caen

                          Country arrow
                          OPRD
                          Not Confirmed

                          Details : Cangrelor is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of ST Elevation Myocardial Infarction.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 16, 2021

                          Lead Product(s) : Cangrelor

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Terumo

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          University Medical Centre Ljubljana

                          Country arrow
                          OPRD
                          Not Confirmed

                          University Medical Centre Ljubljana

                          Country arrow
                          OPRD
                          Not Confirmed

                          Details : Cangrelor is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Out-of-Hospital Cardiac Arrest.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 02, 2019

                          Lead Product(s) : Cangrelor

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Chiesi Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          University of Florida

                          Country arrow
                          OPRD
                          Not Confirmed

                          University of Florida

                          Country arrow
                          OPRD
                          Not Confirmed

                          Details : Cangrelor is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of ST Elevation Myocardial Infarction.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 14, 2017

                          Lead Product(s) : Cangrelor

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Chiesi Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : Cangrelor is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 06, 2016

                          Lead Product(s) : Cangrelor

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : Cangrelor is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Coronary Artery Disease.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 08, 2013

                          Lead Product(s) : Cangrelor

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : Cangrelor is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Coronary Artery Disease.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 13, 2013

                          Lead Product(s) : Cangrelor

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : Cangrelor is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Coronary Artery Disease.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 11, 2013

                          Lead Product(s) : Cangrelor

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank